I-Antibody Entsha Ishintsha Ngokunamandla I-Omicron Nezinhlobonhlobo

Ibhalwe ngu umhleli

I-Sorrento Therapeutics, Inc. namuhla imemezele ukukhishwa kwedatha entsha ye-Omicron variant neutralizing antibody (nAb) STI-9167, COVISHIELD, i-antibody yesiteji esithuthukisiwe etholwe futhi yathuthukiswa ukuze kuhlolwe umtholampilo ngokubambisana okuqhubekayo phakathi kodokotela bamasosha omzimba nodokotela begciwane e-Sorrento nase-Icahn. Isikole Sezokwelapha eMount Sinai eNew York, NY.

Phrinta Friendly, PDF & Imeyili

Izivivinyo zokubopha amaprotheni e-Spike kanye nokuhlolwa kokungathathi hlangothi kusetshenziswa amagciwane amele zonke izinhlobo zokukhathazeka (VOCs) ezaziwayo ze-SARS-CoV-2 seziqediwe nge-STI-9167, futhi le nAb yaqashelwa ukuthi ibopha ngokuhambisana okuphezulu futhi ihlinzeka ngomsebenzi onamandla kakhulu wokungathathi hlangothi (Omicron IC50 = 25 ng/ml). Okubalulekile okuphawuliwe, i-STI-9167 ihlukile uma iqhathaniswa nokuhlolwa kwe-EUA egunyazwe i-SARS-CoV-2 nAbs kulokho okubophayo nokungathathi hlangothi kuyagcinwa kuqhathaniswa nokuhluka okuvelayo kwe-Omicron ne-Omicron (+R346K), okuhlukile ngokwanda kozalo lwe-Omicron lokho. ifaka ukuguqulwa kwephrotheni ye-Spike eyengeziwe engu-R346K. Ukwengeza, i-STI-9167 elawulwa ngethamo eliphansi (5mg/kg) ngemigudu yomlomo noma efakwa emthanjeni inikeze isivikelo esiqinile ngokumelene nezimpawu zomtholampilo zokutheleleka ngokuhlukahluka kwe-Omicron kumodeli yegundane ye-K18-hAce2 ye-COVID-19, ukuvimbela isisindo. ukulahlekelwa kanye nokunciphisa titers zegciwane emaphashini kumazinga angabonakali.

"Isizukulwane kanye nokubonakaliswa kwe-STI-9167 nAb kukhombisa ukusebenzisana okukhulu phakathi kososayensi baseMount Sinai naseSorrento ukubhekana nenkinga yezempilo yomhlaba wonke," kusho uDomenico Tortorella, PhD, uProfesa weMicrobiology e-Icahn Mount Sinai.

“Sikhethe i-antibody STI-9167 kumasethi amakhulu ahlukahlukene alwa ne-SARS-CoV-2 spike neutralizing amasosha omzimba esiwathuthukise kumalebhu ethu. Ikhombise ukusebenza kahle kakhulu kwe-cross-neutralization ngokumelene nazo zonke izigaba ezaziwayo ze-SARS-CoV-2 kanye nokukhathazeka okuhlukahlukene, okuhlanganisa okuhlukile kwe-Omicron ne-Omicron (+R346K) yakamuva,” kuphawula u-J. Andrew Duty, PhD, Umsizi Woprofesa WezeMicrobiology kanye noMqondisi we I-Center for Therapeutic Antibody Development e-Icahn Mount Sinai.

“Ama-nAbs agunyazwe yi-EUA njengamanje anciphise ngokuphawulekayo noma angekho emisebenzini ebophezelayo futhi enza kube lula ngokumelene ne-omicron/omicron (+R346K) okuwenza anganele ukusekela izidingo zamanje zomtholampilo,” kusho uMike A. Royal, MD, JD, MBA, Isikhulu Esiphezulu Sezokwelapha e- I-Sorrento. “Amanye ama-nAbs adingeka kakhulu esikhathini esiseduze, ikakhulukazi ezinganeni ezibonakala zisengozini enkulu yokutheleleka nge-omicron okunzima nokulaliswa esibhedlela. Ukwakheka kwethu kwe-COVIDROPS engaphakathi kwamathumbu kuletha ama-nAbs ethu emigwaqweni yomoya ephezulu lapho i-Omicron cishe izokhomba khona futhi ichume, futhi njengendlela yokwelapha engahlaseli, kulula ukuyiphatha, ilungele izingane. Sesivele siqalile ukwelapha izingane nge-COVIDROPS (nge-STI-2099) e-Mexico lapho ukwahluka kwe-delta kusadlangile. Ngezifundo zeSigaba 2 e-US, e-United Kingdom naseMexico, sibone iphrofayili yokuphepha engalungile yokulethwa kwe-nAbs yethu emakhaleni futhi silindele umphumela ofanayo nge-COVIDROP (nge-STI-9167).”

"Manje sesinolwazi lokuletha izindlela zokwelapha eziningi ze-COVID-19 emtholampilo kanye nokuthuthukela eziningana kwiSigaba 2 kanye/noma nentuthuko ebalulekile," kusho uMark Brunswick, PhD, SVP kanye neNhloko Yezindaba Zokulawula Nekhwalithi eSorrento. "Sisesimweni esihle sokuveza ngokushesha i-COVISHIELD esigabeni se-IND nasemtholampilo futhi silindele ukufaka le IND ebalulekile enyangeni ezayo."

UDkt. Henry Ji, onguSihlalo kanye ne-CEO ye-Sorrento, uphawule wathi, “Umsebenzi owenziwa ngamaqembu e-Sorrento naseNtabeni iSinayi uveze i-antibody emangalisayo enezici eziyingqayizivele nezibalulekile zokuvikela ngokumelene no-Omicron nawo wonke amanye ama-SARS-CoV-2 VOC. I-COVISHIELD yethu yokulwa ne-antibody engathathi hlangothi isezingeni eliphezulu kakhulu futhi iyikhandidethi elithuthuke kakhulu lokulwa ne-Omicron evame kakhulu kanye nama-Omicron asafufusa (+R346K) VOC. Sisebenza ngokuzikhandla ukubeka leli gciwane ukuze lisetshenziswe ezigulini ze-COVID futhi siyaqiniseka ukuthi indlela yethu izohlinzeka ngesixazululo esisebenzayo somtholampilo hhayi nje kuphela esikhathini esiseduze kodwa futhi njengoba lolu bhubhane luqhubeka nokuvela. "

Umbhalo wesandla ophrintiwe ngaphambili wathunyelwa ngoJanuwari 19, 2022 futhi uzoshicilelwa maduze ku-inthanethi ku-biorxiv.org.

I-antibody engathathi hlangothi echaziwe yakhiqizwa ezindaweni zokucwaninga e-Mount Sinai futhi yanikezwa ilayisense ye-Sorrento Therapeutics kuphela. Amalungu e-Mount Sinai kanye namalungu e-Mount Sinai anentshisekelo yezezimali ku-Sorrento Therapeutics.

Phrinta Friendly, PDF & Imeyili

Mayelana umbhali

umhleli

Umhleli omkhulu we-eTurboNew nguLinda Hohnholz. Uzinze e-eTN HQ e-Honolulu, e-Hawaii.

Shiya amazwana

eTurboNews | eTN